<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04796337</url>
  </required_header>
  <id_info>
    <org_study_id>A011-12</org_study_id>
    <nct_id>NCT04796337</nct_id>
  </id_info>
  <brief_title>A Long-term Follow-up Study of Sotatercept for PAH Treatment</brief_title>
  <acronym>SOTERIA</acronym>
  <official_title>An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acceleron Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acceleron Pharma Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to assess the long-term safety, tolerability, and efficacy of&#xD;
      sotatercept in PAH.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Long-term Follow-up Study (LTFU) study is supported by data from the PULSAR study in&#xD;
      which treatment with sotatercept resulted in hemodynamic and functional improvements in the&#xD;
      study participants, including those receiving maximal PAH therapy with double/triple drug&#xD;
      combinations and intravenous prostacyclin.&#xD;
&#xD;
      The primary objective of this open-label, LTFU study is to evaluate the long-term safety and&#xD;
      tolerability of sotatercept when added to background PAH therapy in adult subject with PAH&#xD;
      who have completed prior sotatercept studies.&#xD;
&#xD;
      The secondary objective is to evaluate continued efficacy in adult subject with PAH who have&#xD;
      completed prior sotatercept studies.&#xD;
&#xD;
      Participants eligible to enroll in the study will have participated in and completed the&#xD;
      relevant study requirements of the parent PAH sotatercept clinical studies&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Anticipated">November 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events (AEs)</measure>
    <time_frame>From date of first visit up to 200 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of study participants with detectable anti-drug antibodies (ADA )</measure>
    <time_frame>From date of first visit up to 200 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal hematology laboratory test results</measure>
    <time_frame>From date of first visit up to 200 weeks</time_frame>
    <description>Based upon complete blood cell count, including red blood cell count, absolute white blood cell count, hemoglobin, hematocrit and platelet count</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal clinical chemistry laboratory test results</measure>
    <time_frame>From date of first visit up to 200 weeks</time_frame>
    <description>Based upon blood urea nitrogen, creatinine, total bilirubin, direct bilirubin, AST/ALT, alkaline phosphatase, electrolytes, glucose and carbon dioxide.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of vital signs - body weight</measure>
    <time_frame>From date of first visit up to 200 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of vital signs - blood pressure (systolic/diastolic)</measure>
    <time_frame>From date of first visit up to 200 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of vital signs - electrocardiogram (12-lead) for the determination of QTcF interval</measure>
    <time_frame>From date of first visit up to 200 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal urinalysis results</measure>
    <time_frame>From date of first visit up to 200 weeks</time_frame>
    <description>Based upon dipstick assessment of urine specific gravity, pH, glucose, bilirubin, ketone and protein</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 6-minute walk distance (6MWD)</measure>
    <time_frame>From initiation of treatment Visit 1 to year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum N-Terminal Pro-Hormone B-type Natriuretic Peptide (NT-proBNP)</measure>
    <time_frame>From initiation of treatment Visit 1 to year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WHO Functional Class (FC)</measure>
    <time_frame>From initiation of treatment Visit 1 to year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary vascular resistance (PVR) as determined by right heart catheterization</measure>
    <time_frame>Measured at the year 4 Visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From initiation of treatment Visit 1 to the end of study follow-up Visit 8 weeks after year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who maintain or achieve a low risk score using the simplified French Risk score calculator.</measure>
    <time_frame>From initiation of treatment Visit 1 to year 4</time_frame>
    <description>Composed of the following parameters:&#xD;
WHO FC (I-II)&#xD;
6MWD &gt; 440 meters&#xD;
NT-proBNP &lt; 300 ng/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Borg CR10 Scale (Borg Dyspnea Scale), a measure of exercise tolerance; numerical scale from 0 to 10, with higher number representative of greater exertion.</measure>
    <time_frame>From initiation of treatment Visit 1 to year 4</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>PAH</condition>
  <arm_group>
    <arm_group_label>sotatercept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants rolling over from a blinded parent study will begin sotatercept at a dose of 0.3 mg/kg SC for Visit 1. Dose will escalate to 0.7 mg/kg SC at Visit 2 through remainder of the study. Participants rolling over from an unblinded parent study will continue sotatercept at their current dose and if at dose &lt; 0.7 mg/kg SC can titrate up to 0.7 mg/kg SC for the remainder of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sotatercept</intervention_name>
    <description>sotatercept injection</description>
    <arm_group_label>sotatercept</arm_group_label>
    <other_name>ACE-011</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Eligible participants must meet the following criteria to be enrolled in the study:&#xD;
&#xD;
          1. Participants must have completed their current respective PAH sotatercept clinical&#xD;
             study and its requirements, and must not have discontinued early.&#xD;
&#xD;
          2. Participants must be willing to adhere to the study visit schedule and understand and&#xD;
             comply with all protocol requirements.&#xD;
&#xD;
          3. Participants must have the ability to understand and provide written informed consent.&#xD;
&#xD;
          4. Females of childbearing potential must:&#xD;
&#xD;
               1. Have a negative pregnancy test as verified by the investigator prior to starting&#xD;
                  study drug administration; she must agree to ongoing pregnancy testing during the&#xD;
                  course of the study and until 8 weeks after the last dose of the study drug.&#xD;
&#xD;
               2. If sexually active, have used, and agree to continue to use highly effective&#xD;
                  contraception without interruption, for at least 28 days prior to starting the&#xD;
                  investigational product, during the study (including dose interruptions), and for&#xD;
                  16 weeks (112 days) after discontinuation of study drug.&#xD;
&#xD;
               3. Refrain from breastfeeding a child or donating blood, eggs, or ovum for the&#xD;
                  duration of the study and for at least 16 weeks (112 days) after the last dose of&#xD;
                  study drug.&#xD;
&#xD;
             See Appendix 4 for additional contraceptive information.&#xD;
&#xD;
          5. Male participants must:&#xD;
&#xD;
               1. Agree to use a condom, defined as a male latex condom or non latex condom NOT&#xD;
                  made out of natural (animal) membrane (e.g., polyurethane), during sexual contact&#xD;
                  with a pregnant female or a female of childbearing potential while participating&#xD;
                  in the study, during dose interruptions, and for at least 16 weeks (112 days)&#xD;
                  following investigational product discontinuation, even if he has undergone a&#xD;
                  successful vasectomy.&#xD;
&#xD;
               2. Refrain from donating blood or sperm for the duration of the study and for 16&#xD;
                  weeks (112 days) after the last dose of study drug.&#xD;
&#xD;
          6. Participants must agree not to participate in any other trials of investigational&#xD;
             drugs/devices while they are enrolled in the A011-12 study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants will be excluded from the study if any of the following criteria are met:&#xD;
&#xD;
          1. Not enrolled in a PAH parent study at the time of enrollment.&#xD;
&#xD;
          2. Missed more than the equivalent of 4 consecutive doses between the end of parent study&#xD;
             and the start of this study.&#xD;
&#xD;
          3. Presence of an ongoing serious adverse event that occurred during a PAH sotatercept&#xD;
             clinical study that is assessed to be possibly or probably related to sotatercept.&#xD;
&#xD;
          4. Pregnant or breastfeeding females.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Lu, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Acceleron Pharma Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Manager</last_name>
    <phone>617-649-9200</phone>
    <email>clinicaltrials011@acceleronpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nidhi Samaraweera</last_name>
      <phone>602-271-0832</phone>
      <email>nidhi-research@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Lorraine Stroud</last_name>
      <phone>(602) 271-0832</phone>
      <email>lorraine-research@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jeremy Feldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates P.A.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liyi Fu</last_name>
      <phone>602-258-4951</phone>
      <email>l.fu@pulmonaryassociates.com</email>
    </contact>
    <contact_backup>
      <last_name>Vincent DeLaCruz</last_name>
      <phone>(602) 346-4742</phone>
      <email>vince@pulmonaryassociates.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Baratz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Cygan</last_name>
      <phone>913-588-3855</phone>
      <email>kcygan@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Leslie Spikes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Grace Vayer</last_name>
      <phone>917-620-4191</phone>
      <email>ovayer@bwh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Vercillo</last_name>
      <phone>(917) 620-4191</phone>
    </contact_backup>
    <investigator>
      <last_name>Aaron Waxman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Carl and Edyth Lindner Center for Research and Education at the Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxanne Robertson</last_name>
      <phone>513-585-1777</phone>
      <email>roxanne.robertson@thechristhospital.com</email>
    </contact>
    <contact_backup>
      <last_name>Terri Sikora</last_name>
      <phone>(513) 585-8177 x7</phone>
      <email>terri.sikora@thechristhospital.com</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Engel, MD, FACC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Royanne Holy</last_name>
      <phone>713-363-7536</phone>
      <email>rholy@houstonmethodist.org</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Callender</last_name>
      <phone>(713) 441-7182</phone>
      <email>rcallender@houstonmethodist.org</email>
    </contact_backup>
    <investigator>
      <last_name>Zeenat Safdar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>New Lambton</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Shepherd</last_name>
      <phone>+610249214095</phone>
      <email>julie.shepherd1@health.nsw.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Mercy Kunda</last_name>
      <phone>+610249214095</phone>
      <email>Mercy.kunda@health.nsw.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Glenn Reeves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <state>Hérault</state>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myriam Boulhais</last_name>
      <phone>+33467335937</phone>
      <email>m-boulhais@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sabine Ferre</last_name>
      <phone>+33467335937</phone>
      <email>s-girault@medbiomed.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Arnaud Bourdin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oceane Crebier</last_name>
      <phone>+33476767605</phone>
      <email>ocrebier@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marie Jondot</last_name>
      <phone>+33476765355</phone>
      <email>mjondot@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Bruno Degano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier, Universitaire de Bicêtre</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramdane Meftali</last_name>
      <phone>+33145217892</phone>
      <email>ramdane.meftali@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Ouâffa Sabri</last_name>
      <phone>+33145217916</phone>
      <email>ouaffa.sabri2@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>David Montani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier, Universitaire de Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soud Bezzeghoud</last_name>
      <phone>+33477829448</phone>
      <email>souad.bezzeghoud@chu-st-etienne.fr</email>
    </contact>
    <contact_backup>
      <last_name>Corinne Bernabe</last_name>
      <phone>+33477827348</phone>
      <email>upc@chu-st-etienne.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Laurent Bertoletti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical Center</name>
      <address>
        <city>Ashkelon</city>
        <zip>78306</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amir Bar-Shai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - PPDS</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liora Yehoshua</last_name>
      <phone>+97239377214</phone>
      <email>lioray@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Hilla Levi</last_name>
      <phone>+97236249923</phone>
      <email>hillale1@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Morchedai Kramer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center - PPDS</name>
      <address>
        <city>Ramat-Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariela Velner</last_name>
      <phone>+97235302841</phone>
      <email>ariela.velner@sheba.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Oshrat Yona</last_name>
      <phone>+972542574848</phone>
      <email>oshrat.yona@sheba.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Segel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Dolores Sanz</last_name>
      <phone>+34932275747</phone>
      <email>mdsanz@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Isabel Blanco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28401</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Ochoa</last_name>
      <phone>+34917792642</phone>
      <email>nuriaochoaparra@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Guillermo Moreno</last_name>
      <phone>+34917792642</phone>
      <email>guimoren@ucm.es</email>
    </contact_backup>
    <investigator>
      <last_name>Maria Pilar Escribano Subias, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Alonso Lecue</last_name>
      <phone>+34653359032</phone>
      <email>alonsolecue@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Blanca Sanchez</last_name>
      <phone>+34942204084</phone>
      <email>mblanca.sanchezs@scsalud.es</email>
    </contact_backup>
    <investigator>
      <last_name>Jose Manuel Cifrian Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

